Radius Health (NASDAQ:RDUS) on Wednesday said it had entered into new agreements for the expansion of its Tymlos injection to treat osteoporosis - a condition in which bones become weak and brittle - ...
Radius Reports Positive Phase 3 Results For TYMLOS Subcutaneous Injection In Males With Osteoporosis
(RTTNews) - Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company ...
Tymlos can cause mild to serious side effects. Examples include dizziness, injection site reaction, and nausea. In most cases, side effects caused by Tymlos are temporary. For most people, mild side ...
Abaloparatide-Patch patient assessment study results demonstrated high patient acceptability and self-administration accuracy over a 29-day period Levels of PINP, a biomarker for bone formation, after ...
"The real-world data presented further supports the favorable efficacy and safety profile of TYMLOS and why it is an important treatment option in the management of osteoporosis," said Dr. Felicia ...
“Our focus on postmenopausal osteoporotic-related fracture patients continues to gain traction,” commented Sal Grausso, Chief Commercial Officer for the Company. Grausso added that “We are making ...
Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...
WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing ...
SAN DIEGO -- Treatment with abaloparatide (Tymlos) was safe and effective for men with osteoporosis, according to the phase III ATOM trial. Compared with a 1.2% increase with placebo, men randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback